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Summary The arotinoid Ro 40-8757 was previously shown to inhibit the growth of a variety ofhuman cancer
cell lines derived from breast, lung and uterus. In view of the high incidence of human digestive cancers, and
the slow progress in the development of new therapy, we examined in this paper several combinations between
the new arotinoid Ro 40-8757, 5-fluorouracil (5FU) and interferon a-2a on the growth of nine human cancer
cell lines derived from the gastrointestinal and pancreatic system. Half-maximal inhibition of cell proliferation
by Ro 40-8757 was observed at concentrations ranging between 0.18 and 0.57 um, and increased up to 4.7 gM
in retinoid-resistant CAPAN 620 pancreatic cells. All-trans-retinoic acid was 70 times less potent. The
sensitivity of HT29-5FU-resistant colonic cells was similar to that observed in the parental cells, suggesting an
action independent of pyrimidine metabolism. Ro 40-8757 did not induce any differentiation on HT29 cells, as
suggested by ultrastructural analysis. The arotinoid did not interact with receptor signal transduction pathways
under the control of serum components, such as growth factors as half-maximal inhibition of growth was
similar in HT29-S-B6 cells cultured in the absence or presence of serum. Cell cycle analysis showed that Ro 40-
8757 was not acting at a phase-specific transition in HT29 cells and, accordingly, did not induce overexpression
of the protein kinase C (PKC)a isoform, or conversion of hyperphosphorylated p105 Rb into hypopho-
sphorylated forms. However, the arotinoid induced significant accumulation of the dephosphorylated, active
form of the tumour-suppressor protein. Combinations of Ro 40-8757 with 5FU and interferon a2a resulted in
an additive but not synergistic antiproliferative action in HT29 cells. Our data support the interest in Ro 40-
8757 as a potent anti-cancer drug, especially in combination therapy with 5FU and interferon, in
gastrointestinal and pancreatic cancers, where new active therapeutic modalities are urgently needed.
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The retinoids, including vitamin A and its metabolites, and
synthetic derivatives are very potent drugs affecting cellular
proliferation and differentiation (Hong and Itri, 1994). Thus,
retinoids have been reported to be active in several skin
diseases such as actinic keratosis (Moriarty et al., 1982), oral
leucoplakia (Hong et al., 1986) and xeroderma pigmentosum
(Kraemer et al., 1988). They were also shown to induce
differentiation and to inhibit cell growth in various types of
cancers both in vitro and in vivo (Lippman et al., 1987a,b).
Preclincial studies have led to the development of first- and
second-generation retinoids, used alone or in combination
with cytotoxic drugs, in the treatment of acute promyelocytic
leukaemia (Castaigne et al., 1990; Degos et al., 1995),
advanced squamous cell carcinoma of the cervix (Lippman
et al., 1992), skin cancer (Meyskens et al., 1985) or in the
prevention of second primary cancers in head and neck
carcinoma patients (Hong et al., 1992). In an attempt to find
new indications of retinoids in cancer therapy, many
derivatives have been synthesised. Among these, the third-
generation retinoids, the arotinoids, are of particular interest.
Thus, temarotene (Ro 15-0778) induces regression of
established mammary carcinomas in the rat, without side-
effects that are usually associated with hypervitaminosis A
(Teelman et al., 1988). The most active compound identified
among these third-generation retinoids is Ro 40-8757
mofarotene; 4-[2-[p-[-(E)-2(5,6,7,8-tetrahydro-5,5,8,8-tetrame-
thyl-2-naphthyl) propenyl]ethyl]morpholine]. This compound
is more active than a series of other retinoids tested in rat
mammary cancer (Teelman et al., 1993). It inhibits the
growth of various human cancer cell lines in vitro (Eliason et
al., 1993a) and, moreover, protects the bone marrow from
the toxic effects of cyclophosphamide and 5-fluorouracil
(5FU) in vivo (Eliason et al., 1993b, 1994). In this context, we
found that Ro 40-8757 was the most effective antiprolifera-
tive retinoid, out of 13 compounds tested in a preliminary
screening using the human colon cancer HT29 cell line
(Zimber et al., 1993). This arotinoid was also recently
reported to inhibit oral carcinogenesis in male F344 rats
(Tanaka et al., 1995). In the present work, we have analysed
the antiproliferative effects of Ro 40-8757 in nine human
cancer cell lines originating from the colon, stomach and
pancreas. Cell cycle distribution and expression of the Rbl
retinoblastoma and protein kinase C (PKC)cL mRNA and
proteins, which are involved in cell proliferation and
differentiation (Delage et al., 1993; Buchovich et al., 1989),
were studied in HT29 cells exposed to Ro 40-8757.
Ultrastructural analysis of HT29 cells exposed or not to Ro
40-8757 was performed, and did not show any differentiating
effect of this arotinoid. In addition, we tested the inhibition
of HT29 cell growth by Ro 40-8757 alone or combined with
5FU or interferon a2a (IFN-a2a): combination of retinoids
and interferon was strongly recommended as additive and
synergistic effects between the two drugs have been observed
in various preclinical and clinical situations (Bollag et al.,
1994; Eisenhauer et al., 1994; Toma et al., 1994).
Combination of Ro 40-8757 and 5FU, the most commonly
used drug in gastrointestinal tumour therapy, was performed
in an attempt to eliminate the possibility of any drug
antagonistic effect in this combination.
Materials and methods
Cell lines
The human colon cancer HT29 and CaCo2 cell lines were
obtained from Dr J Fogh (Sloan Kettering Institute for
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Cancer Research, NY, USA). The HT29-S-B6 cell line is a
subclone obtained in our laboratory from the parental HT29
cells after serum deprivation (Forgue-Lafitte, 1989); the
HT29-5FU cell line was obtained from Dr A Zweibaum
(INSERM U178, Villejuif, France). It was selected from the
parental HT29 cells after progressive adaptation to 5FU
(Lesuffleur et al., 1991a). In this cell line, resistance to 5FU
was acquired through thymidylate synthase gene amplifica-
tion (Lesuffleur et al., 1991b). The human gastric cancer cell
lines HGT1, MKN-28 and MKN-74 were established from a
primary tumour localised in the fundus (Laboisse et al., 1982)
or from well-differentiated adenocarcinomas (Hojo et al.,
1977). Human pancreatic cancer cell lines CAPAN 606 and
CAPAN 620 were obtained from E Hollande (University of
Toulouse, France).
Drugs
All-trans retinoic acid, Ro 40-8757 and IFN-a2a were
obtained from Hoffmann-LaRoche (Basle, Switzerland).
5FU was purchased from Sigma (St Louis, MO, USA).
Stock solutions of retinoids were prepared in dimethyl
sulphoxide in the dark, stored at -80°C and diluted in
culture medium immediately before use. 5FU and IFN-a2a
were diluted directly in culture medium.
Culture conditions
Human colon and gastriccancercells werecultured at 37°C in a
95% air/5% carbon dioxide atmosphere in Dulbecco's modified
Eaglemedium(DMEM; Eurobio,Paris, France), supplemented
with 10% fetal calf serum (FCS; Boehringer Mannheim,
Germany), 100 U ml-' penicillin, 100 jug ml streptomycin
and 8 mM glutamine. Colonic and mucin-secreting HT29-S-B6
cells were cultured in a 1:1 mixture of DMEM and Ham F12
nutrient mixture, supplemented with 10 mm glutamine,
transferrin, dextrose (final concentration 4.5 gl-1) and anti-
biotics. Pancreatic CAPAN cells were cultured in RPMI-1640
nutrient medium (Gibco, UK). Culture stocks were maintained
in 100 cm2plasticflasks (Corning, Corning, NY, USA), and the
medium was renewed every 2 days. Cells were passaged weekly
by the trypsin/EDTA procedure.
Cell proliferation
Aliquots of 3 x 105 cells were plated onto 35 mm Petri dishes
and cultured for 2 days in standard conditions before the
addition of drugs. HT29-S-B6 cells were tested in the
presence or absence of 10% FCS. Growth rates were
determined for all cell lines from day 0 to 4. Viability of
cultured cells (adherent and floating) was determined by the
trypan blue exclusion test. Cell numbers were determined
using a Coulter counter ZM (Coultronics, Luton, UK).
Inhibitory potencies for each drug on cell proliferation were
expressed as IC50, defined as the concentration of Ro 40-8757
that induces a 50% growth inhibition after 48 h exposure as
compared with control.
Cell cycle analysis
HT29 cells were cultured in the presence of increasing
concentrations of Ro 40-8757. Cells were harvested by
trypsinisation on day 2, during the exponential phase of
growth and on day 6 at the acquisition of confluence. After
fixation in 70% ethanol, the cell suspensions were studied by
flow cytometry for their DNA content as previously reported
(Forgue-Lafitte et al., 1992).
Northern blot analysis
HT29 cells were washed twice with ice-cold phosphate-
buffered saline (PBS) and then scraped in 4 M guanidinium
isothiocyanate containing 25 mm sodium citrate, 0.1 M 2-
mercaptoethanol, 0.5% sarkosyl at pH 7.0. RNA was
isolated by centrifugation through a cushion of 5.7 M
caesium chloride (Chirgwin et al., 1979). RNA samples
containing 20 Mg of total RNA were electrophoresed through
0.8% agarose-6% formaldehyde gels and blotted onto
Hybond-N nylon membranes in 20 x SSC (1 x SSC corre-
sponds to 0.15 M sodium chloride plus 15 mm sodium
citrate). The membranes were hybridised for 12 h at 42°C
to random-primed 32P-labelled probes. The Rbl probe was
the human cDNA isolated from the pCVM-HRB plasmid,
kindly provided by Dr R Weinberg (Cambridge, USA). The
PKCax probe was the 1294 bp fragment of the human cDNA,
isolated after EcoRI digestion from the phPKC-cx7 plasmid,
kindly provided by Dr N M Sposi. After hybridisation, blots
were washed at high stringency (0.1 x SSC, 0.1% sodium
dodecyl sulphate (SDS) at 57°C) and autoradiographed.
Ribosomal RNA was used as a reference for homogeneity of
loading, and molecular weight markers were included.
Western blot analysis
Total cellular extracts were prepared in sample buffer
containing 8 M urea, 5% SDS, 5% 2-mercaptoethanol, 10%
glycerol, 0.02% bromophenol blue, Tris-base (pH 6.8).
Aliquots of 25 Mg of protein were electrophoresed through
SDS-polyacrylamide gel containing 6-7.5% acrylamide and
0.1% SDS. Proteins were transferred to nitrocellulose filter
membranes (Bio-Rad Laboratories, Richmond, CA). The
membranes were briefly stained with Ponceau S to mark the
position of molecular weight standards and to assess equal
transfer of proteins, then blocked for 1 h at 37°C with 3%
bovine serum albumin (BSA) and 0.05% Nonidet in Tris-
sodium chloride buffer (50 mM Tris-base, 150 mM sodium
chloride, pH 7.6)) and incubated for 1 h at room temperature
with the appropriate antibodies. The rabbit anti-Rbl PAb
C15 from Santa Cruz Biotechnology (Tebu, France) was used
at a 1:100 dilution. The PKCoc specific antibody (Blobe GC,
1993) was a gift from Dr Y Hannun (Durham, NC, USA).
The immunoblots were then washed in Tris-saline buffer,
incubated for 1 h at 22°C with a 1:1000 dilution ofpolyclonal
sheep anti-rabbit immunoglobulin antibody conjugated with
horseradish peroxidase, and probed using the enhanced
chemiluminescence system (ECL, Amersham, UK).
Electron microscopy
HT29 cells treated for 12 days with Ro 40-8757 at the
concentration of 3 x 10-5 M were processed for transmission
electron microscopy, as described previously (Chastre et al.,
1993).
Statistical evaluation
Results of cell proliferation data are expressed as means+s.d.
of at least three independent experiments using two
determinations for each cell count. Differences between
means were analysed using Student's t-test, with P<0.05
being considered statistically significant.
Results
Inhibition of cellproliferation by Ro 40-8757
Inhibition of tumour cell proliferation by Ro 40-8757 was
observed in a dose-dependent manner in all the cell lines
examined, as shown in Figure 1 for HT29 cells. Half-maximal
inhibition was observed at 0.43 x 10'6 M Ro 40-8757. For
comparison, Table I summarises the inhibitory potency of Ro
40-8757 on cell growth (IC50 values) in several cancer cell
lines derived from the human digestive tract. The IC50 values
were below 10-6 M Ro 40-8757, except in the pancreatic
CAPAN 620 cell line (IC50=4.7+2.9 x 10-6 M). All-trans
retinoic acid was approximately 70 times less potent than Ro
40-8757 (IC50 = 3 x 10- 5 M) in the cancer cell lines examined
in the present study.Anti-proliferative effects of the arotinoid Ro 40-8757
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Cell cycle
Three different concentrations of Ro 40-8757 were tested in
HT29 cells for 2 or 6 days. No difference in the percentage of
cells in GO-GI, S or G2 phases was observed between control
and treated cells after 2 days in culture (Figure 2). At day 6,
control cells and cells exposed to the lower concentration of
Ro 40-8757 were at confluence. The percentages of cells at
GO-GI transition was therefore increased. However, after 6
days of treatment with the highest concentration of Ro 40-
8757 (10-6 M), the distribution of cells in the various phases
of the cell cycle was in the same range as observed after 2
days. We therefore conclude that Ro 40-8757 is not acting at
a specific phase of the HT29 cell cycle.
Ultrastrucutral analysis
Electron microscopic examination did not reveal any
differentiation-inducing effect of Ro 40-8757 on HT29
parental cells in terms of cell polarity, appearance of
microvilli, tight junctions and desmosomes, or cytoplasmic
mucin formation.
p105 Rb and PKCoa expression
Recent advances in the molecular genetics of colon cancer
pointed out the major contributions of p105 Rb and PKC in
the oncogenic and mitogenic regulation of signal transduction
systems from the cytoplasm to the nucleus (Buchovitch et al.,
1989; Delage et al., 1993; Chastre et al., 1993). The status of
the tumour-suppressor gene Rbl is strongly associated with
cell proliferation, depending on the phosphorylation status of
the p105 Rb protein (Buchovitch et al., 1989; Ewen, 1994).
The membrane-bound activated PKC is also involved in the
regulation of cell proliferation, and PKCa is a major isoform
detected in colonic epithelial cells (Nishizuka, 1986). In this
connection, we previously established that tumour progres-
sion induced by oncogenic ras in human colonic CaCo2 cells
is associated with PKCoa gene overexpression (Delage et al.,
1993). Since the arotinoid exerts antiproliferative effects in
human colonic cells HT29, we analysed here the p105 Rb and
PKCac status by Northern and Western blotting in control
and treated cells cultured in the presence of 3 x 10- 7 M Ro-
40-8757. As shown in Figure 3 I, the retinoid did not increase
the accumulation of the Rbl message in HT29 cells at the
exponential phase of growth or after confluence. In contrast,
Ro 40-8757 treatment induced a significant accumulation of
both unphosphorylated and phosphorylated forms of Rb
protein (Figure 3 II). However, Ro 40-8757 did not induce
the conversion of hyperphosphorylated forms into hypopho-
sphorylated Rbl. In comparison, normal human colonic
crypts exclusively exhibited hypophosphorylated Rbl (Na-
gano et al., 1995), which is consistent with a negative control
of proliferation in normal mucosa (Figure 3 II). In contrast,
no difference was observed in the expression ofPKCa mRNA
and protein in HT29 cells after treatment with Ro 40-8757
(Figure 3 III and IV).
Inhibition of cell proliferation by combination of Ro 40-8757,
5FU and IFN-a2a
We have tested several combinations of Ro 40-8757 with
5FU and IFN-a2a in HT29 cells. Additive but no synergistic
nor antagonistic effects were observed for the combinations
of Ro 40-8757 and IFN-cx2a or 5FU (Figure 4). When the
three drugs were combined at concentrations corresponding
to their half-maximal inhibitory effects, more than 80%
inhibition was observed (Figure 4).
Discussion
New therapeutic agents and strategies are expected in the
treatment of gastrointestinal and pancreatic cancers when
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Figure 1 Antiproliferative effect of Ro 40-8757 in the HT29
human colonic cell line. HT29 cells were exposed for the indicated
time to various concentrations of Ro 40-8757: 10-7 M (-El-);
3 x 10 7M (-_-); 10 6M (-0-); or 3 x 10 6M (-V-). The cell
count was determined in comparison with control HT29 cells
(-M-). Data from one experiment representative of seven others
performed in duplicate (standard variation < + 10%).
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Figure 2 Cell cycle parameters in HT29 colonic cells cultured in
the absence (control) or presence of various concentrations of Ro
40-8757 for 2 days. Representative experiment out ofthree (values
varied <5% between separate experiments).
Table I Inhibitory potency (IC50X 10-6M) of Ro 40-8757 on the proliferation of human gastrointestinal tumour cell lines
Colon Stomach Pancreas
HT29-S-B6 HT29-S-B6
HT29 HT29-SFU FCS- FCS+ CaCo2 HGTI MKN28 MKN74 CAPAN 606 CAPAN 620
0.43 0.57 0.40 0.24 0.18 0.45 0.42 0.25 0.41 4.70
+0.15 +0.45 +0.29 +0.14 +0.05 +0.39 +0.30 +0.09 +0.40 +2.91
Data are means +s.d. ofthree independent experiments performed in duplicate for each cell line. FCS, cell culture in the presence or absence of
fetal calf serum.
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Figure 3 p105 Rb and PKCcx status in the HT29 human colonic cell line, not treated (control) or treated with the arotinoid Ro 40-
8757 (3 x i-7M). I-plO5 Rb, Northern blot (1, exponential phase; 2, at confluence; a, control; b, treated). II-plO5 Rb, Western blot
(same legends as I-, except for 3, human normal colon). III-PKCa, Northern blot (same legend as I-). IV-PKCa, Western blot (same
legend as I-).
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Figure 4 Antiproliferative effect of Ro 40-8757, 5FU and IFN
alone or in combinations in the HT29 human colonic cell line.
Cultured HT29 cells were treated for 2 days with the following
drugs: Ro 40-8757 (3 x 10-7M); 5FU (2 x 10-7M); IFN
(lOOOUml-'). *P<0.05; **P<0.01 Data are means+s.d. of
three separate experiments performed in duplicate.
5FU remains the main cytotoxic drug used. The low toxicity
of 5FU observed in clinical trials allows the combination of
folinic acid and 5FU with other drugs. Some anti-cancer
drugs are currently under investigation, including new
cytotoxic compounds such as CPT 1, gemcitabine, oxalipla-
tin or tomudex, and immune components such as MAb 17-
lA. The arotinoid Ro 40-8757 is known to inhibit the growth
of a variety of transformed cells derived from breast, lung or
uterus cancers (Eliason et al., 1994). In this report, we
demonstrate that this new drug also exerts remarkable
antiproliferative effects in human cancer cell lines derived
from the digestive tract, without inducing differentiation in
the parental HT29 colonic cell line. However, clinical trials
are needed before drawing any conclusion as in vitro
chemosensitivity studies are not always predictive of in vivo
activity. Moreover, drug exposure at the concentrations used
in this study could perhaps not be obtained in vivo without
significant toxicity.
The mechanism of action of the arotinoid Ro 40-8757 is
not yet known. Although the structure of Ro 40-8757 is
related to retinoic acid, it differs from classical retinoids (all-
trans and 13-cis) as it does not bind to any of nuclear retinoic
acid receptors identified so far (RAR-oc, -fi, -y, RXR-cx -fi, -,y),
and it does not regulate retinoic acid response element
(RARE)-dependent transcription (Eliason et al., 1993a).
Moreover, it does not reproduce the all-trans retinoic acid-
induced granulocytic differentiation in HL60 human promye-
locytes (Eliason et al., 1993a). An antiproliferative effect in
human breast cancer cells of another synthetic retinoid
(AHPN), which is also independent of RAR or RXR
binding, was recently reported (Shao et al., 1995). Ro 40-
8757 could act through other retinoid receptors, recently
described as 'orphan receptors' (Mangelsdorf and Evans,
1995). Previous reports on the effects of classical retinoic
acids in gastrointestinal malignancies were disappointing
(Hong et al., 1994). In the present study, all-trans retinoic
acid was about 70 times less potent than Ro 40-8757 in
producing the same antiproliferative effect in HT29 cells.
Our data demonstrate that Ro 40-8757 does not induce
any phase-specific blockade in the HT29 cell cycle, as
reported for two human breast cancer cell lines (Eliason et
al., 1994b). Several target sites and metabolic effects might be
involved in the antiproliferative action of this compound.
Some other cytostatic drugs, such as nitrosoureas or
bleomycin, are also non-cell cycle phase specific (Skeel et
al., 1995), and this hypothesis is sustained by our data on the
Rbl status in HT29 cells exposed to this retinoid. Hypopho-
sphorylated forms of plO5Rb are known to inhibit cell
proliferation at the GI phase of the cell cycle through
physical association and sequestration of key transcription
factors such as E2F, leading to inhibition of E2F-mediated
transactivation (Chellapah et al., 1991). Several genes
encoding cell cycle regulators harbour promoters containing
E2F binding sites that contribute to the expression of myc,
cdc2 and the effectors of DNA synthesis: thymidine kinase,
thymidylate synthase, dihydrofolate reductase and DNA
polymerase a (Dyson et al., 1994). Furthermore, E2F-pRb
complexes dissociate before the GI/S boundary upon pRbl
phosphorylation (Cao et al., 1992). In HT29 cells, Ro 40-
8757 does not induce the conversion of hyperphosphorylated
Rb into hypophosphorylated p105 forms, while only
hypophosphorylated Rbl was detected in freshly isolated
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normal human colonic epithelial crypts (Figure 4). However,
the antiproliferative action of the arotinoid may be partly
explained by increased levels of hypophosphorylated plO5Rb
as the amount of the active Rb form of this tumour-
suppressor protein plays an important role in the regulation
of oncogenic and mitogenic pathways via interactions with
nuclear transcription factors or tyrosine kinases (Craven et
al., 1995; Muller, 1995). In contrast, PKCoa gene expression
and accumulation of the encoded protein were unchanged in
HT29 cells after Ro 40-8757 treatment.
Additional information concerning the mechanism of
action of Ro 40-8757 on cell proliferation could be drawn
from the present study. (1) The sensitivity of HT29-5FU cells
to Ro 40-8757 was in the same range as that of parental
HT29 cells. Moreover, the most sensitive cell line to Ro 40-
8757 in our study is the CaCo2 line, established from a
patient who relapsed after 5FU treatment. These data suggest
an action independent ofpyrimidine metabolism. (2) The IC50
values for this drug are in the same range for HT29-S-B6
cultured in the presence or absence of FCS, demonstrating a
serum-independent action of Ro 40-8757. We can assume
that the arotinoid does not interact with receptor signal
transduction pathways under the control of serum compo-
nents such as mitogenic growth factors. (3) We previously
reported that the antiproliferative effect of Ro 40-8757 was
identical in mdrl-negative and -positive breast cancer cell
lines (Louvet et al., 1994), suggesting that the turnover of this
retinoid is not affected by the P-glycoprotein pump, one of
the most common mechanisms of chemoresistance in
gastrointestinal tumors. (4) In agreement with data reported
by Eliason et al. (1994b), we have also found that this
arotinoid inhibited cell growth without affecting cell viability.
Recently, Ushida et al. (1994) showed that Ro 40-8757
induces a down-regulation of the transcription of the
mitochondrial gene encoding for a subunit of the NADH
dehydrogenase, which may explain in part the antiprolifera-
tive effect of this compound. This down-regulation seems to
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40-8757 did not induce any HT29 cell differentiation or
selection of a differentiated cell subpopulation. (6) Combina-
tions of Ro 40-8757 with 5FU and/or IFN-a2a resulted in an
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In conclusion, the arotinoid Ro 40-8757 inhibits the
growth of several tumour cell lines derived from the human
digestive system, in 5FU-sensitive as well as in 5FU-resistant
cells. However, in view of the possible divergence between in
vitro and in vivo results, clinical trials are needed in order to
ascertain whether the in vitro growth inhibition reported
herein will translate into clinical effects. Further investiga-
tions on the mechanism of action of this promising retinoid
are therefore needed. However, from a clinical point of view,
our results suggest a possible beneficial effect of Ro 40-8757
in combination with 5FU and IFN-a2a. This is also in line
with the fact that anti-cancer therapy is mainly based on the
association of several drugs with different mechanisms of
action. Thus, Ro 40-8757 is a new potent anti-cancer drug,
and deserves further development, especially in gastrointest-
inal and pancreatic tumours for which new active drugs are
urgently needed.
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